Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03675308




Registration number
NCT03675308
Ethics application status
Date submitted
12/09/2018
Date registered
18/09/2018
Date last updated
18/06/2024

Titles & IDs
Public title
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
Scientific title
A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)
Secondary ID [1] 0 0
2017-002465-22
Secondary ID [2] 0 0
M16-011
Universal Trial Number (UTN)
Trial acronym
KEEPsAKE 1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Psoriatic Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Placebo
Treatment: Other - Risankizumab

Placebo comparator: Placebo - Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.

Experimental: Risankizumab - Participants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.


Treatment: Other: Placebo
Placebo for risankizumab administered by subcutaneous injection

Treatment: Other: Risankizumab
Risankizumab administered by subcutaneous injection
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24
Timepoint [1] 0 0
Baseline and Week 24
Secondary outcome [1] 0 0
Change From Baseline In Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24
Timepoint [1] 0 0
Baseline and Week 24
Secondary outcome [2] 0 0
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 Response at Week 24
Timepoint [2] 0 0
Baseline and Week 24
Secondary outcome [3] 0 0
Percentage of Participants With an ACR20 Response at Week 16
Timepoint [3] 0 0
Baseline and Week 16
Secondary outcome [4] 0 0
Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24
Timepoint [4] 0 0
Week 24
Secondary outcome [5] 0 0
Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 24
Timepoint [5] 0 0
Baseline and Week 24
Secondary outcome [6] 0 0
Change From Baseline in Fingernail-Physician Global Assessment (PGA-F)
Timepoint [6] 0 0
Baseline and Week 24
Secondary outcome [7] 0 0
Percentage of Participants With Resolution of Enthesitis at Week 24
Timepoint [7] 0 0
Week 24
Secondary outcome [8] 0 0
Percentage of Participants With Resolution of Dactylitis at Week 24
Timepoint [8] 0 0
Week 24
Secondary outcome [9] 0 0
Change From Baseline in PsA Modified Total Sharp Score (mTSS) at Week 24
Timepoint [9] 0 0
Baseline and Week 24
Secondary outcome [10] 0 0
Change From Baseline In 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
Timepoint [10] 0 0
Baseline and Week 24
Secondary outcome [11] 0 0
Change From Baseline In Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24
Timepoint [11] 0 0
Baseline and Week 24
Secondary outcome [12] 0 0
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 24
Timepoint [12] 0 0
Baseline and Week 24
Secondary outcome [13] 0 0
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 24
Timepoint [13] 0 0
Baseline and Week 24

Eligibility
Key inclusion criteria
* Clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for PsA (CASPAR) at the Screening Visit.
* Participant has active disease at Baseline defined as = 5 tender joints (based on 68 joint counts) and = 5 swollen joints (based on 66 joint counts)
* Diagnosis of active plaque psoriasis with at least one psoriatic plaque of = 2 cm diameter or nail changes consistent with psoriasis at Screening Visit.
* Participant has demonstrated an inadequate response or intolerance to or contraindication for conventional synthetic disease modifying anti-rheumatic drugs (csDMARD) therapy(ies).
* Presence of either at Screening:

* = 1 erosion on radiograph as determined by central imaging review or;
* High sensitivity C-reactive protein (hsCRP) = 3.0 mg/L.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Participant is considered by investigator, for any reason, to be an unsuitable candidate for the study.
* Participant has a known hypersensitivity to risankizumab.
* Participant has previous treatment with biologic agent.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/03/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
28/09/2026
Actual
Sample size
Target
Accrual to date
Final
964
Recruitment in Australia
Recruitment state(s)
ACT,QLD,SA,VIC
Recruitment hospital [1] 0 0
The Canberra Hospital /ID# 207592 - Garran
Recruitment hospital [2] 0 0
Royal Brisbane and Women's Hospital /ID# 212785 - Herston
Recruitment hospital [3] 0 0
Rheumatology Research Unit Sunshine Coast /ID# 207200 - Maroochydore
Recruitment hospital [4] 0 0
Griffith University /ID# 207505 - Southport
Recruitment hospital [5] 0 0
Flinders Medical Centre /ID# 210562 - Bedford, Park
Recruitment hospital [6] 0 0
Emeritus Research /ID# 207202 - Camberwell
Recruitment hospital [7] 0 0
Monash Medical Centre /ID# 208034 - Clayton
Recruitment postcode(s) [1] 0 0
2605 - Garran
Recruitment postcode(s) [2] 0 0
4029 - Herston
Recruitment postcode(s) [3] 0 0
4558 - Maroochydore
Recruitment postcode(s) [4] 0 0
4222 - Southport
Recruitment postcode(s) [5] 0 0
5042 - Bedford, Park
Recruitment postcode(s) [6] 0 0
3124 - Camberwell
Recruitment postcode(s) [7] 0 0
3168 - Clayton
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Montana
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
United States of America
State/province [23] 0 0
West Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Wisconsin
Country [25] 0 0
Argentina
State/province [25] 0 0
Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Ciuadad Autonoma De Buenos Aires
Country [27] 0 0
Argentina
State/province [27] 0 0
Santa Fe
Country [28] 0 0
Argentina
State/province [28] 0 0
Tucuman
Country [29] 0 0
Argentina
State/province [29] 0 0
Cordoba
Country [30] 0 0
Argentina
State/province [30] 0 0
San Miguel de Tucuman
Country [31] 0 0
Belgium
State/province [31] 0 0
Oost-Vlaanderen
Country [32] 0 0
Belgium
State/province [32] 0 0
Genk
Country [33] 0 0
Belgium
State/province [33] 0 0
Merksem
Country [34] 0 0
Bosnia and Herzegovina
State/province [34] 0 0
Republika Srpska
Country [35] 0 0
Bosnia and Herzegovina
State/province [35] 0 0
Sarajevo
Country [36] 0 0
Brazil
State/province [36] 0 0
Bahia
Country [37] 0 0
Brazil
State/province [37] 0 0
Minas Gerais
Country [38] 0 0
Brazil
State/province [38] 0 0
Parana
Country [39] 0 0
Brazil
State/province [39] 0 0
Rio Grande Do Sul
Country [40] 0 0
Brazil
State/province [40] 0 0
Sao Paulo
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Pleven
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Sofia
Country [43] 0 0
Canada
State/province [43] 0 0
British Columbia
Country [44] 0 0
Canada
State/province [44] 0 0
Manitoba
Country [45] 0 0
Canada
State/province [45] 0 0
Ontario
Country [46] 0 0
Canada
State/province [46] 0 0
Quebec
Country [47] 0 0
Canada
State/province [47] 0 0
Saskatchewan
Country [48] 0 0
Chile
State/province [48] 0 0
Providencia
Country [49] 0 0
Chile
State/province [49] 0 0
Santiago
Country [50] 0 0
Chile
State/province [50] 0 0
Vitacura Santiago
Country [51] 0 0
Croatia
State/province [51] 0 0
Grad Zagreb
Country [52] 0 0
Croatia
State/province [52] 0 0
Osjecko-baranjska Zupanija
Country [53] 0 0
Croatia
State/province [53] 0 0
Primorsko-goranska Zupanija
Country [54] 0 0
Croatia
State/province [54] 0 0
Splitsko-dalmatinska Zupanija
Country [55] 0 0
Croatia
State/province [55] 0 0
Zagreb
Country [56] 0 0
Czechia
State/province [56] 0 0
Brno
Country [57] 0 0
Czechia
State/province [57] 0 0
Praha
Country [58] 0 0
Czechia
State/province [58] 0 0
Uherske Hradiste
Country [59] 0 0
Denmark
State/province [59] 0 0
Hovedstaden
Country [60] 0 0
Denmark
State/province [60] 0 0
Midtjylland
Country [61] 0 0
Estonia
State/province [61] 0 0
Harjumaa
Country [62] 0 0
Estonia
State/province [62] 0 0
Tartumaa
Country [63] 0 0
Finland
State/province [63] 0 0
Uusimaa
Country [64] 0 0
Finland
State/province [64] 0 0
Kuopio
Country [65] 0 0
Finland
State/province [65] 0 0
Turku
Country [66] 0 0
Germany
State/province [66] 0 0
Nordrhein-Westfalen
Country [67] 0 0
Germany
State/province [67] 0 0
Berlin-buch
Country [68] 0 0
Germany
State/province [68] 0 0
Frankfurt
Country [69] 0 0
Germany
State/province [69] 0 0
Hamburg
Country [70] 0 0
Greece
State/province [70] 0 0
Attiki
Country [71] 0 0
Greece
State/province [71] 0 0
Kriti
Country [72] 0 0
Greece
State/province [72] 0 0
Thessaloniki
Country [73] 0 0
Greece
State/province [73] 0 0
Athens
Country [74] 0 0
Greece
State/province [74] 0 0
Patras
Country [75] 0 0
Israel
State/province [75] 0 0
Tel-Aviv
Country [76] 0 0
Israel
State/province [76] 0 0
Ashkelon
Country [77] 0 0
Israel
State/province [77] 0 0
Haifa
Country [78] 0 0
Israel
State/province [78] 0 0
Kfar Saba
Country [79] 0 0
Israel
State/province [79] 0 0
Petakh Tikva
Country [80] 0 0
Italy
State/province [80] 0 0
Emilia-Romagna
Country [81] 0 0
Italy
State/province [81] 0 0
Ancona
Country [82] 0 0
Italy
State/province [82] 0 0
Catania
Country [83] 0 0
Italy
State/province [83] 0 0
Rome
Country [84] 0 0
Italy
State/province [84] 0 0
Verona
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Seoul Teugbyeolsi
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Daegu
Country [87] 0 0
Latvia
State/province [87] 0 0
Adazi
Country [88] 0 0
Latvia
State/province [88] 0 0
Liepaja
Country [89] 0 0
Latvia
State/province [89] 0 0
Riga
Country [90] 0 0
Lithuania
State/province [90] 0 0
Kaunas
Country [91] 0 0
Lithuania
State/province [91] 0 0
Klaipeda
Country [92] 0 0
Lithuania
State/province [92] 0 0
Siauliai
Country [93] 0 0
Malaysia
State/province [93] 0 0
Negeri Sembilan
Country [94] 0 0
Malaysia
State/province [94] 0 0
Perak
Country [95] 0 0
Malaysia
State/province [95] 0 0
Selangor
Country [96] 0 0
Malaysia
State/province [96] 0 0
Kuala Lumpur
Country [97] 0 0
Mexico
State/province [97] 0 0
Ciudad De Mexico
Country [98] 0 0
Mexico
State/province [98] 0 0
Jalisco
Country [99] 0 0
Mexico
State/province [99] 0 0
Nuevo Leon
Country [100] 0 0
Mexico
State/province [100] 0 0
Yucatan
Country [101] 0 0
Mexico
State/province [101] 0 0
Ciudad de Mexico
Country [102] 0 0
Mexico
State/province [102] 0 0
Mexico City
Country [103] 0 0
Netherlands
State/province [103] 0 0
Fryslan
Country [104] 0 0
Netherlands
State/province [104] 0 0
Groningen
Country [105] 0 0
Netherlands
State/province [105] 0 0
Leeuwarden
Country [106] 0 0
New Zealand
State/province [106] 0 0
Auckland
Country [107] 0 0
New Zealand
State/province [107] 0 0
Waikato
Country [108] 0 0
New Zealand
State/province [108] 0 0
Burwood
Country [109] 0 0
Poland
State/province [109] 0 0
Kujawsko-pomorskie
Country [110] 0 0
Poland
State/province [110] 0 0
Malopolskie
Country [111] 0 0
Poland
State/province [111] 0 0
Mazowieckie
Country [112] 0 0
Poland
State/province [112] 0 0
Podlaskie
Country [113] 0 0
Poland
State/province [113] 0 0
Warminsko-mazurskie
Country [114] 0 0
Portugal
State/province [114] 0 0
Porto
Country [115] 0 0
Portugal
State/province [115] 0 0
Viana Do Castelo
Country [116] 0 0
Portugal
State/province [116] 0 0
Aveiro
Country [117] 0 0
Portugal
State/province [117] 0 0
Braga
Country [118] 0 0
Portugal
State/province [118] 0 0
Lisboa
Country [119] 0 0
Puerto Rico
State/province [119] 0 0
San Juan
Country [120] 0 0
Romania
State/province [120] 0 0
Timis
Country [121] 0 0
Romania
State/province [121] 0 0
Bucuresti
Country [122] 0 0
Romania
State/province [122] 0 0
Cluj-Napoca
Country [123] 0 0
Romania
State/province [123] 0 0
Iasi
Country [124] 0 0
Russian Federation
State/province [124] 0 0
Moskva
Country [125] 0 0
Russian Federation
State/province [125] 0 0
Novosibirskaya Oblast
Country [126] 0 0
Russian Federation
State/province [126] 0 0
Sankt-Peterburg
Country [127] 0 0
Russian Federation
State/province [127] 0 0
Tatarstan, Respublika
Country [128] 0 0
Russian Federation
State/province [128] 0 0
Moscow
Country [129] 0 0
Russian Federation
State/province [129] 0 0
Perm
Country [130] 0 0
Russian Federation
State/province [130] 0 0
Ulyanovsk
Country [131] 0 0
Serbia
State/province [131] 0 0
Beograd
Country [132] 0 0
Serbia
State/province [132] 0 0
Vojvodina
Country [133] 0 0
Singapore
State/province [133] 0 0
Singapore
Country [134] 0 0
Slovakia
State/province [134] 0 0
Biely Kostol
Country [135] 0 0
Slovakia
State/province [135] 0 0
Martin
Country [136] 0 0
Slovakia
State/province [136] 0 0
Nove Mesto nad Vahom
Country [137] 0 0
Slovakia
State/province [137] 0 0
Piestany
Country [138] 0 0
Slovakia
State/province [138] 0 0
Poprad
Country [139] 0 0
South Africa
State/province [139] 0 0
Eastern Cape
Country [140] 0 0
South Africa
State/province [140] 0 0
Gauteng
Country [141] 0 0
South Africa
State/province [141] 0 0
Western Cape
Country [142] 0 0
Spain
State/province [142] 0 0
Barcelona
Country [143] 0 0
Spain
State/province [143] 0 0
A Coruna
Country [144] 0 0
Spain
State/province [144] 0 0
Almeria
Country [145] 0 0
Spain
State/province [145] 0 0
Madrid
Country [146] 0 0
Spain
State/province [146] 0 0
Valencia
Country [147] 0 0
Sweden
State/province [147] 0 0
Orebro Lan
Country [148] 0 0
Sweden
State/province [148] 0 0
Skane Lan
Country [149] 0 0
Sweden
State/province [149] 0 0
Falun
Country [150] 0 0
Sweden
State/province [150] 0 0
Solna
Country [151] 0 0
Sweden
State/province [151] 0 0
Uppsala
Country [152] 0 0
Sweden
State/province [152] 0 0
Vasteras
Country [153] 0 0
Taiwan
State/province [153] 0 0
Chia-Yi
Country [154] 0 0
Taiwan
State/province [154] 0 0
Taichung
Country [155] 0 0
Taiwan
State/province [155] 0 0
Taoyuan City
Country [156] 0 0
Ukraine
State/province [156] 0 0
Kharkivska Oblast
Country [157] 0 0
Ukraine
State/province [157] 0 0
Vinnytska Oblast
Country [158] 0 0
Ukraine
State/province [158] 0 0
Cherkasy
Country [159] 0 0
Ukraine
State/province [159] 0 0
Chernihiv
Country [160] 0 0
Ukraine
State/province [160] 0 0
Kharkiv
Country [161] 0 0
Ukraine
State/province [161] 0 0
Khmelnytskyi
Country [162] 0 0
Ukraine
State/province [162] 0 0
Kryvyi Rih
Country [163] 0 0
Ukraine
State/province [163] 0 0
Kyiv
Country [164] 0 0
Ukraine
State/province [164] 0 0
Lutsk
Country [165] 0 0
Ukraine
State/province [165] 0 0
Lviv
Country [166] 0 0
Ukraine
State/province [166] 0 0
Poltava
Country [167] 0 0
Ukraine
State/province [167] 0 0
Zaporizhzhia
Country [168] 0 0
United Kingdom
State/province [168] 0 0
London, City Of
Country [169] 0 0
United Kingdom
State/province [169] 0 0
Scotland
Country [170] 0 0
United Kingdom
State/province [170] 0 0
Staffordshire
Country [171] 0 0
United Kingdom
State/province [171] 0 0
Manchester
Country [172] 0 0
United Kingdom
State/province [172] 0 0
Portsmouth
Country [173] 0 0
United Kingdom
State/province [173] 0 0
Torquay
Country [174] 0 0
United Kingdom
State/province [174] 0 0
Wirral

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
Trial website
https://clinicaltrials.gov/study/NCT03675308
Trial related presentations / publications
Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, Wang Z, Soliman AM, Eldred A, Barcomb L, Behrens F. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis. 2022 Feb;81(2):225-231. doi: 10.1136/annrheumdis-2021-221019. Epub 2021 Dec 15.
Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, Soliman AM, Eldred A, Barcomb L, Behrens F. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology (Oxford). 2023 Jun 1;62(6):2113-2121. doi: 10.1093/rheumatology/keac607.
Thakre N, D'Cunha R, Goebel A, Liu W, Pang Y, Suleiman AA. Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis. Rheumatol Ther. 2022 Dec;9(6):1587-1603. doi: 10.1007/s40744-022-00495-0. Epub 2022 Sep 30.
Kristensen LE, Soliman AM, Papp K, White D, Barcomb L, Lu W, Eldred A, Behrens F. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1. Rheumatology (Oxford). 2023 Feb 1;62(2):629-637. doi: 10.1093/rheumatology/keac342.
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03675308